TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02879773

Intervention type: RADIATION
Intervention: CTPVe
Description: Non contrast computed tomography (CTPVe) scan during end inspiration and end expiration in supine position

Intervention type: RADIATION
Intervention: CTPVe
Description: Non contrast computed tomography (CTPVe) scan during end inspiration and end expiration in supine position
Study: NCT04228393

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 6-mercaptopurine
Description: 6-mercaptopurine was administered orally to patients once daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 6-mercaptopurine
Description: 6-mercaptopurine was administered orally to patients once daily.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard treatment
Description: The initial dose is 50mg/m2. The dose was adjusted according to white blood cells.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Individualized treatment
Description: The initial dose is determined according to the genotypes of patients combined with Clinical Pharmacogenetics Implementation Consortium (CPIC). The dose was adjusted according to white blood cells, genotypes and the concentrations of 6-TGN in red blood cells.
Study: NCT04493580

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: iDBT
Description: Electronic DBT sessions designed to mirror in-person DBT.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: In-Person DBT
Description: In-person DBT
Study: NCT00496223

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib
Description: Sunitinib will be given PO once daily on days 1-14 of each 21 day cycle. The exact dose of sunitinib will be determined during the Phase I part of the trial.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dacarbazine
Description: Dacarbazine will be given at 1000 mg/m2 on day 1 of every 21 day cycle.
Study: NCT03174249

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exposure therapy
Description: Daily training at an in-patient ward during four plus four weeks, separated by a home training period of 6-8 weeks.
Study: NCT04228783

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad26.ZEBOV
Description: Participants will receive IM injection (0.5 mL) of Ad26.ZEBOV as Dose 1 (5\*10\^10 vp, Lot A, B, and C) on Day 1 (Groups 1, 2, 3 and 5) and an Ad26.ZEBOV booster dose on Day 177 (Group 5).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad26.ZEBOV
Description: Participants will receive IM injection (0.5 mL) of Ad26.ZEBOV as Dose 1 (5\*10\^10 vp, Lot A, B, and C) on Day 1 (Groups 1, 2, 3 and 5) and an Ad26.ZEBOV booster dose on Day 177 (Group 5).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad26.ZEBOV
Description: Participants will receive IM injection (0.5 mL) of Ad26.ZEBOV as Dose 1 (5\*10\^10 vp, Lot A, B, and C) on Day 1 (Groups 1, 2, 3 and 5) and an Ad26.ZEBOV booster dose on Day 177 (Group 5).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad26.ZEBOV
Description: Participants will receive IM injection (0.5 mL) of Ad26.ZEBOV as Dose 1 (5\*10\^10 vp, Lot A, B, and C) on Day 1 (Groups 1, 2, 3 and 5) and an Ad26.ZEBOV booster dose on Day 177 (Group 5).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA-BN-Filo
Description: Participants will receive IM injection (0.5 mL) of MVA-BN-Filo as Dose 2 (1\*10\^8 Inf U, Lot 1, 2, 3 and 5) on Day 57.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA-BN-Filo
Description: Participants will receive IM injection (0.5 mL) of MVA-BN-Filo as Dose 2 (1\*10\^8 Inf U, Lot 1, 2, 3 and 5) on Day 57.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA-BN-Filo
Description: Participants will receive IM injection (0.5 mL) of MVA-BN-Filo as Dose 2 (1\*10\^8 Inf U, Lot 1, 2, 3 and 5) on Day 57.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA-BN-Filo
Description: Participants will receive IM injection (0.5 mL) of MVA-BN-Filo as Dose 2 (1\*10\^8 Inf U, Lot 1, 2, 3 and 5) on Day 57.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive IM injection (0.5 mL) of placebo (0.9 % saline) as Dose 1 on Day 1, followed by placebo as Dose 2 on Day 57 (Groups 4 and 6) and a booster of matching placebo on Day 177 (Group 6).

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive IM injection (0.5 mL) of placebo (0.9 % saline) as Dose 1 on Day 1, followed by placebo as Dose 2 on Day 57 (Groups 4 and 6) and a booster of matching placebo on Day 177 (Group 6).
Study: NCT05430321

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Assessment of physiological parameters
Description: FT implementation begins 3 minutes before the procedures and 10 minutes continuous. After the end of the procedures further 3 minutes was given . Physiological parameters were simultaneously recorded on the registration form

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Assessment of Stress
Description: Newborn Stress Scale (NSS) was used end of the all procedures which means 13th minute.
Study: NCT03038451

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-NOR (s-amlodipine) 2,5 mg & 5 mg tablet
Study: NCT02907268

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: onabotulinumtoxinA
Description: OnabotulinumtoxinA (Botox; Allergan) was approved by the FDA in 2002. Intervention administered by study nurse. Intradermal administered in a regular 1 cm2 grid across the cheeks and forehead. Intramuscular administered as per normal practice.
Study: NCT01639664

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High doses CPFA
Description: High doses CPFA (coupled plasma-filtration adsorption) with AMPLYA™ (BELLCO ITALY): \>0.20 L/kg/day of plasma treated in the first 3 days after randomization.
Study: NCT01924364

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tissue Genesis Cell Isolation System™ (TGI CIS)
Description: In this study, we will concentrate the adipose stromal cells (ASCs) in the fat graft material to assess whether this modification will increase fat graft retention over time. The concentrated fat to be injected into the subject from the fat grafting procedure will be processed by the Tissue Genesis Cell Isolation System™ (CIS) device. The volume retention in areas treated with ASC concentrated fat grafts will be compared with regions treated with standard fat grafts in the same patient. Additionally, data from our current study assessing volume retention after fat grafting for facial deformities (IRB # PRO09060101, NCT01345591) will be used for comparison.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Standard of care fat grafting
Description: In this study, we will concentrate the adipose stromal cells (ASCs) in the fat graft material to assess whether this modification will increase fat graft retention over time.
Study: NCT02966340

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prazosin
Description: 2mg Prazosin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prazosin
Description: 2mg Prazosin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo
Study: NCT03694938

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magnetic resonance imaging
Description: Annually magnetic resonance imaging
Study: NCT01360216

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LARC education and training
Description: A CME/CEU accredited Grand Rounds education and training session will be given to clinicians and contraceptive educators practicing in clinics assigned to the intervention arm. Clinicians will have hands-on training as well. The half-day session emphasizes evidence-based contraceptive counseling and provision.
Study: NCT02907268

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: onabotulinumtoxinA
Description: OnabotulinumtoxinA (Botox; Allergan) was approved by the FDA in 2002. Intervention administered by study nurse. Intradermal administered in a regular 1 cm2 grid across the cheeks and forehead. Intramuscular administered as per normal practice.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: abobotulinumtoxinA
Description: AbobotulinumtoxinA (Dysport; Galderma) was approved by the FDA in 2009. Intervention administered by study nurse. Intradermal administered in a regular 1 cm2 grid across the cheeks and forehead. Intramuscular administered as per normal practice.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: abobotulinumtoxinA
Description: AbobotulinumtoxinA (Dysport; Galderma) was approved by the FDA in 2009. Intervention administered by study nurse. Intradermal administered in a regular 1 cm2 grid across the cheeks and forehead. Intramuscular administered as per normal practice.
Study: NCT01358773

Intervention type: OTHER
Group type: OTHER
Intervention: multidisciplinary intervention
Description: Comparison of the polysomnography results, blood collection parameters, resting metabolic rate values, body composition variables, carotid artery thickness values, abdominal and subcutaneous fat and lung function variables baseline, middle and at the end of the one year of interdisciplinary weight loss program combined exercise training with physiotherapy, clinical, nutritional and psychological therapies.
Study: NCT03071146

Intervention type: DEVICE
Intervention: Bard® LifeStent® 5F Vascular Stent System
Description: The LifeStent® Vascular Stent is a peripheral stent intended to improve luminal diameter in the treatment of symptomatic de-novo or restenotic lesions up to 240 mm in length in the native superficial femoral artery (SFA) and popliteal artery with reference vessel diameters ranging from 4.0 - 6.5 mm.
Study: NCT03210623

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: stent retriever(TonbridgeMT)
Description: mechanical thrombectomy with stent retriever(TonbridgeMT), digital subtraction angiography(DSA), computed tomography(CT), magnetic resonance imaging (MRI), diffusion weighted imaging (DWI)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Solitaire™
Description: mechanical thrombectomy with Solitaire™ , digital subtraction angiography(DSA), computed tomography(CT), magnetic resonance imaging(MRI), diffusion weighted imaging(DWI)
Study: NCT04469075

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clindamycin Phosphate
Description: phosphate 1% solution triamcinolone 0.01% at every array change (or approved equivalent)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triamcinolone Acetonide
Description: triamcinolone acetonide 0.01% lotion triamcinolone 0.01% at every array change
Study: NCT04677790

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: assigned period of specific dietary restrictions
Description: Step by step gradual introduction of egg containing food products

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: assigned period of specific dietary restrictions
Description: Step by step gradual introduction of egg containing food products
Study: NCT03352479

Intervention type: OTHER
Group type: OTHER
Intervention: Opioid Return
Description: Calculate the percentage of prescribed to returned opioids
Study: NCT05430321

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Assessment of Comfort
Description: Neonatal Comfort Behavior Scale (NCBS) was used end of the all procedures which means 13th minute.
Study: NCT03709472

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computer Assisted CIFFTA
Description: This is a hybrid intervention that includes individual work with the adolescent (e.g., Motivational Interviewing, diary card identification of triggers), computer assisted psychoeducational work, and intensive family therapy interventions.
Study: NCT03825523

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: iART
Description: After group assignment, ART will be started within the first 48 hours after admission to the hospital. ART regimen will be decided according to each subject´s the clinical characteristics

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: cART
Description: After group assignment, ART is started at the discretion of the attending physician. ART regimen will be decided according to each subject´s the clinical characteristics
Study: NCT04375618

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RhEGF
Description: The EGF impregnated membrane will be placed upon the recession site and will be stabilized by suturing it to the lingual papillae using 4-0 absorbable sutures. The flap will be coronally advanced as far as possible to cover the membrane and will be sutured to the buccal interdental papillae with 4-0 absorbable sutures (Trulenetm, Healthium Medtech Pvt Ltd, Bangalore, India). Standard recall and maintenance regimen will be followed and subjects will be encouraged to report to the department on a monthly basis.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Plain Collagen
Description: A collagen membrane without FGF-2 will be used.
Study: NCT04377243

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: V8
Description: one pill per day either V8 or placebo

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V8
Description: one pill per day either V8 or placebo
Study: NCT00678340

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: WACA and PVI
Description: Wide area circumferential ablation (WACA) in the pulmonary vein antrum with subsequent pulmonary vein isolation (PVI) with a single tip irrigated catheter.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PVAC
Description: Circumferential ablation with a circular ablation catheter (Ablation Frontiers) to electrical silence.
Study: NCT02217709

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: phenelzine sulfate
Description: Given by mouth

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Ancillary studies
Study: NCT03113357

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Myofascial release technique
Description: myofascial release technique take along about 3 minutes. This phase repeated 3 times in each session. At the end, for more release, sub-occipital traction will commence. The subject lies supine with head supported and therapist places the three middle fingers just caudal to the nuchal line, lifts the finger tips upward resting the hands on the treatment table, and then applies a gentle cranial pull, causing a long axis extension. The procedure is performed for 2 to 3 minutes. Subjects in each group received ten physical therapy treatment sessions. Treatment frequency was six times per week for MFR group and every day for exercise group which three times per week have been come to clinical center for checking of exercise by physiotherapist

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: conventional exercise therapy
Description: All exercises were performed to a count of 7 seconds and subjects were instructed to perform all exercises daily, 15 repetitions each (twice a day). Treatment frequency was every day for exercise group which three times per week have been come to clinical center for checking of exercise by physiotherapist. They also could be taught active muscle stretching exercises to address any muscle tightness assessed to be present.
Study: NCT01610024

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Beetroot Juice
Description: Give subjects 500ml beetroot juice in the 24 hour period prior to class begins. They will receive this during 3 of the 6 weeks
Study: NCT01634854

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vaginal Misoprostol
Description: Dosage: 25 µg every 4 hours up to a maximum of 4 doses until cervical change is consistent with a diagnosis of active labor Route of administration: Intravaginal

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous Oxytocin
Description: Dosage: 2 miu per minute increased in increments of 1-2 miu per minute every 30 minutes to establish an effective contraction pattern.~Route of administration: intravenous
Study: NCT03699254

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valganciclovir
Description: Valganciclovir is a L-valyl ester of ganciclovir that exists as a mix of 2 diastereomers. After administration, both are converted to ganciclovir by esterases. Ganciclovir is a synthetic analogue of 2'-deoxyguanosine, it inhibits replication of cytomegalovirus.~In CMV-infected cells it's phosphorylated (phosphorylation is dependent on the viral kinase and occurs preferentially in virus-infected cells). Ganciclovir activity is due to inhibition of viral DNA synthesis by ganciclovir triphosphate.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valganciclovir
Description: Valganciclovir is a L-valyl ester of ganciclovir that exists as a mix of 2 diastereomers. After administration, both are converted to ganciclovir by esterases. Ganciclovir is a synthetic analogue of 2'-deoxyguanosine, it inhibits replication of cytomegalovirus.~In CMV-infected cells it's phosphorylated (phosphorylation is dependent on the viral kinase and occurs preferentially in virus-infected cells). Ganciclovir activity is due to inhibition of viral DNA synthesis by ganciclovir triphosphate.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ganciclovir
Description: Ganciclovir is a synthetic analogue of 2'-deoxyguanosine, it inhibits replication of cytomegalovirus.~In CMV-infected cells it's phosphorylated (phosphorylation is dependent on the viral kinase and occurs preferentially in virus-infected cells). Ganciclovir activity is due to inhibition of viral DNA synthesis by ganciclovir triphosphate.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ganciclovir
Description: Ganciclovir is a synthetic analogue of 2'-deoxyguanosine, it inhibits replication of cytomegalovirus.~In CMV-infected cells it's phosphorylated (phosphorylation is dependent on the viral kinase and occurs preferentially in virus-infected cells). Ganciclovir activity is due to inhibition of viral DNA synthesis by ganciclovir triphosphate.
Study: NCT06713785

Intervention type: DRUG
Group type: OTHER
Intervention: Amlodipine
Description: Amlodipine 1mg/ml Oral Solution

Intervention type: DRUG
Group type: OTHER
Intervention: Amlodipine
Description: Amlodipine 1mg/ml Oral Solution
Study: NCT03709472

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral: Traditional face-to-face treatment-no technology
Description: Community agencies provide mostly individual counseling but may add some family involvement in treatment planning.
Study: NCT00128141

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tactile stimulus
Description: four times a day
Study: NCT02191124

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paroxetine
Description: Patients in both groups (MBC or ST) receive open-label paroxetine (20-60mg/day) within the therapeutic dose range recommended by the Guidelines for the Prevention and Treatment of Major Depression in China.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paroxetine
Description: Patients in both groups (MBC or ST) receive open-label paroxetine (20-60mg/day) within the therapeutic dose range recommended by the Guidelines for the Prevention and Treatment of Major Depression in China.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mirtazapine
Description: Patients in both groups (MBC or ST) receive open-label mirtazapine (15-45mg/day) within the therapeutic dose range recommended by the Guidelines for the Prevention and Treatment of Major Depression in China

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirtazapine
Description: Patients in both groups (MBC or ST) receive open-label mirtazapine (15-45mg/day) within the therapeutic dose range recommended by the Guidelines for the Prevention and Treatment of Major Depression in China
Study: NCT02754128

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: BeFAST
Description: The motor learning (ML)-based gait-related training program is designed to improve advanced gross motor skills and athleticism. It will involve 45-min sessions twice to three times weekly over 6 weeks for a total of 16 active sessions. A maximum of 7 weeks will be permitted. Each session will consist of 35-min of active training along with a 10-min active warm-up/cool-down that incorporates ML. Children will be given a 3- to 5-min mental motor imagery script to practice on days when they do not have active training sessions. The total number of sessions (combined training/home imagery) will be five per week.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: BeSTRONG
Description: The functional strength training program is designed to improve gait-related skills. It will involve 45-min sessions twice to three times weekly over 6 weeks for a total of 16 active sessions. A maximum of 7 weeks will be permitted. Each session will consist of 35-min of active training along with a 10-min active warm-up/cool-down. Children will be given a 3- to 5-min home program of strength exercises to practice on days when they do not have active training sessions. The total number of sessions (combined training/home program) will be five per week.
Study: NCT00802373

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Solifenacin succinate
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tolterodine
Description: Oral
Study: NCT02701608

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levofloxacin
Description: levofloxacin 500 mg x1/day (for patients ≤70kg) or levofloxacin 750 mg x1/day (for patients \>70kg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampicin
Description: rifampicin 600mg x1/day (for patients ≤70kg) or rifampicin 900mg x1/day (for patients \>70kg)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional IV treatment of staphylococci IE following European guidelines 2015 including cloxacilline, oxacilline,gentamicine,vancomycine,rifampicine
Description: Conventional IV treatment of staphylococci IE following European guidelines 2015 including cloxacilline, oxacilline,gentamicine,vancomycine,rifampicine
Study: NCT04436133

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Biological/Vaccine: 11-valent recombinant human papilloma virus vaccine (Hansenula polymorpha)
Description: Inject vaccine produced by ChinaVaccineSerum, containing HPV antigen protein, 270μg/1ml per bottle

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 9-valent HPV vaccine（Gardasil 9）
Description: Inject Gardasil 9 , containing HPV antigen protein, 270μg/0.5ml per bottle